fashion -WSS

fashion

author：comprehensive 2025-09-27 23:03:26 - browse：96

Adam's take main illustration — Molly Ferguson/STAT

The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York investigation that raised serious doubts about the science underpinning the company’s experimental drug simufilam.

Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studies is the ethically correct thing to do.The FDA has the power to place clinical holds on experimental drugs when there’s evidence of an unacceptable safety risk to study participants. Simufilam doesn’t appear to be toxic. It’s not causing dangerous side effects. But study participants can also be harmed when they volunteer for a clinical trial based on false or misleading information about a drug’s potential efficacy.

The CUNY committee charged with investigating Cassava’s principal scientific collaborator, the neuroscientist Hoau-Yan Wang, could not definitively prove that Wang faked simufilam data, but that’s only because he refused to turn over original data and primary research records that the committee had requested to examine. Wang also claimed that boxes of research records relevant to the investigation were thrown away. The investigative report was first made public last week in the journal Science.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： How I helped Pfizer think through the ethics of Viagra

explore

knowledge

WSS

First Opinion Podcast: What happens when kids become caregivers?

Health insurers say they are turning to AI to cut costs, improve care

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

'Null' research findings aren't empty of meaning. Let's publish them

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

A controversial new treatment promises to make little people taller

leisure time

fashion

hotspot

Apple is now the first public company to be valued at $3 trillion

Akili, maker of video game for ADHD, to be acquired for 34 million

New air purifier tech could be key to improving indoor air quality

Health insurers say they are turning to AI to cut costs, improve care

Duchenne breakthrough therapy leaves behind pioneering families

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare slashes safety net hospital payments by nearly $1 billion

DIEP, the 'gold standard' of breast reconstruction, is under threat

2 officers injured in shooting in Orlando, police say

focus

The a glaring gap in research on serious mental illness and primary care

Group behind ProMed defends move to subscription

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Average age of first period drops to 11.9 years, study shows

The a glaring gap in research on serious mental illness and primary care

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

focus

explore

knowledge

entertainment